4//SEC Filing
Versi Jannine 4
Accession 0001839882-23-013974
CIK 0000887247other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:14 PM ET
Size
19.8 KB
Accession
0001839882-23-013974
Insider Transaction Report
Form 4
Versi Jannine
Director
Transactions
- Award
Series E Convertible Preferred Stock
2023-05-25+1,941.2→ 1,941.2 total(indirect: By LLC)From: 2023-05-25→ Common Stock (1,941,200 underlying) - Award
Employee Stock Option (Right to Buy)
2023-05-25+5,144→ 5,144 totalExercise: $2.90From: 2023-05-25Exp: 2030-02-19→ Common Stock (5,144 underlying) - Award
Employee Stock Option (Right to Buy)
2023-05-25+5,144→ 5,144 totalExercise: $2.90From: 2023-05-25Exp: 2031-02-19→ Common Stock (5,144 underlying) - Award
Employee Stock Option (Right to Buy)
2023-05-25+5,144→ 5,144 totalExercise: $2.90From: 2023-05-25Exp: 2032-02-19→ Common Stock (5,144 underlying) - Award
Common Stock
2023-05-25+177,194→ 177,194 total(indirect: By LLC) - Award
Employee Stock Option (Right to Buy)
2023-05-25+5,144→ 5,144 totalExercise: $2.90From: 2023-05-25Exp: 2028-02-19→ Common Stock (5,144 underlying) - Award
Employee Stock Option (Right to Buy)
2023-05-25+5,144→ 5,144 totalExercise: $2.90From: 2023-05-25Exp: 2029-02-19→ Common Stock (5,144 underlying)
Footnotes (5)
- [F1]On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F2]The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the trustee of. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interests therein.
- [F3]Received in exchange for shares of common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.
- [F4]Received in the Merger by virtue of the assumption of a stock option to acquire shares of DMK common stock in connection with the Merger, with proportionate adjustments to the number of shares subject to the option and the per share exercise price.
- [F5]Received in the Merger in exchange for shares of common stock of DMK. Each whole share of Series E Preferred Convertible Stock is convertible into 1,000 shares of Adamis common stock at the election of the Reporting Person provided that no portion of the Series E Convertible Preferred Stock may be converted if the Reporting Person or her affiliates own in excess of 9.99% of the number of shares of Adamis common stock outstanding immediately after giving effect of such conversion. On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.
Documents
Issuer
Adamis Pharmaceuticals Corp
CIK 0000887247
Entity typeother
Related Parties
1- filerCIK 0001977745
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:14 PM ET
- Size
- 19.8 KB